Life-Changing TEER Therapy for Select Patients with Mitral Regurgitation
MitraClip™ is the world’s first mitral transcatheter edge-to-edge repair (TEER) therapy -- also referred to as TMVr (transcatheter mitral valve repair) -- that delivers a minimally invasive treatment option for select patients with primary or secondary mitral regurgitation (MR) who would otherwise go untreated.1,2 With more than 20 years of clinical experience and over 200,000 patients treated worldwide, MitraClip™ is a well-established procedure with the highest-reported to date MR reduction, proven safety and survival, and durable clinical outcomes.3,5
Learn about the clinical performance of the MitraClip™ TEER System.
Tailored. Optimized. Proven.
At Abbott, we continue to innovate with the fourth-generation MitraClip™ device. MitraClip™ G4 features several enhancements that offer physicians more treatment options that can be tailored to a patients' unique mitral valve anatomy.
Expanded Range of Clip Sizes
A total of 4 clip sizes—now including clips with wider grasping area1,4—gives physicians the ability to choose a clip size based on each patient’s mitral valve anatomy.5,6,9,10
Controlled Gripper Actuation (CGA)
With more options to confirm and optimize leaflet grasping, CGA allows physicians to grasp leaflets simultaneously or independently.1,4
Predictable Procedure Experience4
Precision and stability from a delivery system specifically designed for the mitral valve facilitates Left Atrial Pressure (LAP) monitoring.4
Both AHA/ACC/HFSA and the ACC/AHA Guidelines Favor Intervention
Transcatheter edge-to-edge repair (TEER) therapy is recommended by the 2022 AHA/ACC/HFSA7 and the 2020 ACC/AHA Guideline8 for select primary and secondary* MR patients. Determining the severity of MR is an important factor in the management of the condition. The guidelines support aggressive monitoring and early action, with the goal of preventing complications due to left ventricular volume overload.7
*Secondary MR patients with persistent symptoms despite optimal guideline-directed medical therapy (GDMT).

Ordering Information
MitraClip™ G4 System
Product Code | Description | Piece Count |
---|---|---|
MCG40100 | MitraClip G4 System | 1 |
CDS0706-NT | MitraClip G4 NT Clip Delivery System | 1 |
CDS0706-NTW | MitraClip G4 NTW Clip Delivery System | 1 |
CDS0706-XT | MitraClip G4 XT Clip Delivery System | 1 |
CDS0706-XTW | MitraClip G4 XTW Clip Delivery System | 1 |
SGC0701 | MitraClip G4 Steerable Guide Catheter | 1 |
Required Accessories
Product Code | Description | Piece Count |
---|---|---|
SZR01ST | Stabilizer | 1 |
LFT01ST | Lift | 1 |
PLT01ST | Support Plate | 1 |
References
- MitraClip G4 Instructions for Use.
- Lim DS, et al. Improved functional status and quality of life in prohibitive surgical risk patients with degenerative mitral regurgitation after the transcatheter mitral valve repair. J Am Coll Cardiol. 2014;64(2):182-192.
- Data on file at Abbott.
- Tests performed by and data on file at Abbott.
- von Bardeleben R, Mahoney P, Morse M, et al. 1-Year Outcomes With Fourth-Generation Mitral Valve Transcatheter Edge-to-Edge Repair From the EXPAND G4 Study. J Am Coll Cardiol Intv. 2023 Nov, 16 (21) 2600-2610.
- Maisano F. Clip Selection Strategy with 4th Generation MitraClip™: Evidence-Based Recommendations from the Global EXPAND Study. Data presented at PCR London Valves 2022.
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022 May;79(17):e263-e421
- Otto C, et al. 2020 ACC/AHA Guideline for the Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Corrected version. Circ. 2021;143(5):e72-e227.
- von Bardeleben, R, Rogers, J, Mahoney, P. et al. Real-World Outcomes of Fourth-Generation Mitral Transcatheter Repair: 30-Day Results From EXPAND G4. J Am Coll Cardiol Intv. 2023 Jun, 16 (12) 1463–1473.
- Rogers, J, Asch, F, Sorajja, P. et al. Expanding the Spectrum of TEER Suitability: Evidence From the EXPAND G4 Post Approval Study. J Am Coll Cardiol Intv. 2023 Jun, 16 (12) 1474–1485.
MAT-2100249 v4.0
Stay Connected